Physicians' Academy for Cardiovascular Education

Progressive CAD despite low LDL-C, an elusive disease?

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema

New recommendations of the ESC/ESH Guidelines on the management of hypertension

3' education - Feb. 11, 2019 - Prof. Bryan Williams - London, UK

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Get involved in May Measurement Month to increase awareness of elevated blood pressure

3' education - Feb. 6, 2019 - Prof. Neil Poulter - London, UK

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot

Diabetes & CVD: Time for a multifactorial approach

10' education - Dec. 6, 2018 - WCC Dubai, UAE - John E Deanfield, MD London, United Kingdom

Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit?

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Neil Poulter MD - London, UK

Novel therapeutic diabetes approaches: The cardiovascular benefits beyond glucose control

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Lina Badimon, MD Barcelona, Spain

Aspirin for primary prevention of CV events: yes or no?

3' education - Jan. 30, 2019 - Prof. dr. Freek Verheugt - Amsterdam, The Netherlands

Translating mechanisms to CV benefits of GLP-1RAs and SGLT2 inhibitors

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

Cholesterol guidelines in need of major changes?

5' education - Jan. 25, 2019 - Kausik Ray, François Mach

What is the science and outcome supporting lower LDL-c targets?

5' education - Jan. 23, 2019 - John Kastelein, Lluis Masana

LDL-c as target in cardiology: The road towards lower targets

5' education - Jan. 22, 2019 - John Kastelein, Chris Packard

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands

Guidelines and the role of non-statin therapies for high risk ASCVD patients

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands

A clinical view on BET inhibition in targeting residual risk in CVD and diabetes

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Kausik Ray, MD - London, UK

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France

Moving to benefit-based medicine with a lifetime risk model

10' education - Dec. 10, 2018 - ESC 2018 - Munich, Germany - Prof. Frank Visseren - Utrecht, The Netherlands

Sustained LDL-c reduction upon dose adjustment of PCSK9 inhibitor

Literature - Feb. 20, 2019 - Dufour R et al., - J Clin Lipidol. 2019

In an open-label extension study, consistent and sustained LDL-c reduction was seen upon changing the dose of alirocumab based on LDL-c level, allowing for an individualized approach.

Striking underuse of therapies for HFrEF not explained by low blood pressure

Literature - Feb. 19, 2019 - Peri-Okonny PA et al., - JACC : Heart Failure 2019

The contemporary CHAMP-HF registry of HFrEF patients revealed that <10% of patients eligible for ACEi/ARB/ARNI and BB therapy received target doses, also when SBP was >110 mmHg.

Long-term statin adherence inversely associated with all-cause mortality in ASCVD

Literature - Feb. 19, 2019 - Rodriguez F et al. - JAMA Cardiol 2019
A retrospective cohort study found that low adherence to long-term statin therapy was associated with a higher risk of all-cause mortality in patients with ASCVD.

A retrospective cohort study found that low adherence to long-term statin therapy was associated with a higher risk of all-cause mortality in patients with ASCVD.

Diet with red meat as main protein source increases levels of TMAO, which is linked to atherogenesis

Literature - Feb. 19, 2019 - Wang Z et al., - Eur Heart J 2019

Consuming a diet with red meat as the main protein source for 4 weeks results in substantial increases in gut-microbiota-produced TMAO levels, as compared with isocaloric white meat and non-meat diets.

Bariatric surgery in obese subjects with hypertension results in improved BP outcomes

Literature - Feb. 19, 2019 - Schiavon CA et al. - Hypertension. 2019

Bariatric surgery in obese subjects with hypertension resulted in reduced need for antihypertensive medication with similar ABPM profile and nondipping status, and reduced BP variability and lower number of patients with resistant hypertension compared to medical therapy.

Increasing prevalence rates of modifiable risk factors in relatively young patients hospitalized for AMI

Literature - Feb. 19, 2019 - Yandrapalli S et al. - JACC 2019
In a retrospective cohort study, major modifiable atherosclerotic risk factors were highly prevalent among adults aged 18-44 years hospitalized for a first AMI. Except for dyslipidemia, prevalence rates of risk factors progressively increased over time.

In a retrospective cohort study, major modifiable atherosclerotic risk factors were highly prevalent among adults aged 18-44 years hospitalized for a first AMI. Except for dyslipidemia, prevalence rates of risk factors progressively increased over time.

Large meta-analysis confirms efficacy of statins in primary CVD prevention, but individual benefit-harm profiles vary

Literature - Feb. 18, 2019 - Yebyo HG et al. - Am Heart J 2019

This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.

DPP-4 inhibitor meets primary endpoint in CV outcome trial

News - Feb. 14, 2019

The long-term CAROLINA trial met its primary endpoint, defined as non-inferiority of linagliptin vs. glimepiride in time to first occurrence of 3P-MACE in adults with T2DM .

Progressive CAD despite low LDL-C, an elusive disease?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema
In patients with progressive CAD, stabilizing or even regression of disease is possible, targeting a combination of risk factors. Prof. Ray and Prof. Jukema discuss the importance of LDL-c lowering to halt progression.

In patients with progressive CAD, stabilizing or even regression of disease is possible, targeting a combination of risk factors. Prof. Ray and Prof. Jukema discuss the importance of LDL-c lowering to halt progression.

Reversal agent for factor Xa inhibitors effective in patients with major bleeding on factor Xa inhibiting therapy

Literature - Feb. 12, 2019 - Connolly SJ et al. - N Engl J Med. 2019

In ANNEXA-4, andexanet alfa infusion resulted in rapid reversal of anti-factor Xa activity and excellent or good hemostatic efficacy at 12 hours was achieved in 82% of patients with major bleeding.

Treatment with GLP-1RA results in reduction of MACE in type 2 diabetes patients with established CVD

Literature - Feb. 12, 2019 - Hernandez AF et al. - The Lancet 2018

Albiglutide was superior to placebo with respect to MACE in T2DM patients in the Harmony Outcomes trial without differences in serious adverse events.

AF patients with cognitive impairment or frailty less likely to receive OAC

Literature - Feb. 12, 2019 - Madhavan M et al. - Am Heart J 2019

In the ORBIT-AF multicenter cohort study, AF patients with cognitive impairment or frailty showed higher stroke risk and mortality, but OACs were underprescribed. The conditions did not affect OAC treatment effect.